Close
FINDING CURES TOGETHER<sup>SM</sup>

Hematologic Malignancies: Translating Discoveries to Novel Therapies

Continuing Medical Education (CME)

Accreditation Statement
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement

The AACR has designated this live activity for a maximum of 26.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey (available here as the meeting approaches) by Tuesday, Nov. 4, 2014. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Statement of Educational Need, Target Audience, and Learning Objectives
It is estimated that over 156,000 new cases of one of the hematologic malignancies will occur in 2014. Leukemia and non-Hodgkin lymphoma are two of the top 10 cancer types in estimated new cases and estimated deaths in both men and women in the United States in 2014. Acute lymphocytic leukemia is estimated to be the most common type of newly diagnosed cancer in children (ages 0-14) in 2014, accounting for about 26 percent of new pediatric cancer cases.

These statistics are meant to demonstrate that the many diseases, their variety of subtypes, and associated disorders categorized as hematologic malignancies still remain a prevalent threat to public health despite the many recent advances in the field of research and treatment. Successful treatment has come from the biological understanding and correct diagnosis of malignancy subtype facilitated by great advances to the field of genomics in general. This conference will address many of the advances in genomic profiling, clinical genomics, and technologies in plenary session presentations and a panel discussion on practical implementation of clinical genomics into one’s institution.

Currently, more than 50 individual drugs (alone or in combination with other treatment modalities) are used to treat patients with blood cancers, with many new drugs in clinical trials. Additionally, these drugs can often be used to treat multiple blood cancers and in response to initial drug resistance. Treatments include immunomodulators (ex. Lenalidomide), those in epigenetic therapy (ex. azacitidine, entinostat, panobinostat, targeting epigenetic regulator genes), monoclonal antibodies or antibody-drug conjugates (ex. rituximab and brentuximab vedotin) and other advances in immunotherapy (CAR T cell therapy).

Current drugs, new therapies, and insight into the most effective treatment are rooted in basic cancer research discoveries in fields like epigenetics, immunology, the tumor microenvironment, stem cells, and cell death pathways. The organizers of the conference selected these topics as some of the most current areas where basic cancer research is able to directly translate to therapeutic development and treatment.

Additionally, the conference will allow those seeking credit to engage in practical panel discussions with key thought leaders on the challenges and opportunities of drug development and clinical research in hematologic malignancies.

After participating in this CME activity, physicians should be able to:

  • Analyze current basic and translational cancer research in the fields of tumor microenvironment and metabolism, cell death pathways and stem cells, and identify potential applications to the clinic;

  • Provide examples of the latest research in immunotherapy and epigenetic therapy for hematologic malignancies;

  • Demonstrate knowledge of current advances in genomics and explain how genomics can assist in diagnostics and treatment options;

  • Articulate the challenges and opportunities in drug development and clinical research in hematologic malignancies; and

  • Integrate and network with colleagues across hematologic malignancy type and with solid tumor colleagues.

Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR will provide information that Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

Acknowledgement of Financial or Other Support
This activity is supported by grants which will be disclosed at the activity.

Questions About CME?
Please contact the Office of CME at 215-440-9300 or cme@aacr.org.